Dual Antiplatelet Therapy and Very Early Neurological Deterioration after Non-Cardioembolic Stroke According to Stroke Etiology Authors: Rosa Sruthy Pereppadan, Sabrina Schärli, Shania Brülisauer, Francesco Valletta, Dimitrios Vlachos, Thomas R. Schneider, Victoria Hellstern, Gian Marco De Marchis, Tolga D. Dittrich Published: 2026 ABSTRACT AbstractIntroductionEarly neurological deterioration after ischemic stroke is associated with worse clinical outcome, yet little is known about the frequency and determinants of neurological worsening during the first 24 h after admission. Dual antiplatelet therapy (DAPT) is recommended early after minor non-cardioembolic stroke to reduce recurrent ischemic events, but its relationship with very early deterioration (vEND) and potential differences across stroke etiologies remain unclear.MethodsWe conducted a retrospective single-center cohort study including consecutive adults with non-cardioembolic ischemic stroke admitted to a Swiss tertiary stroke center between 2014 and 2023. vEND was defined as neurological worsening within 24 h using 2 thresholds (NIHSS increase ≥4 points [primary] and ≥2 points [secondary]). Patients were categorized according to antiplatelet strategy (newly initiated DAPT vs. single antiplatelet therapy [SAPT]) and stroke etiology (large artery atherosclerosis [LAA] vs. non-LAA). Associations between antiplatelet therapy and vEND were analyzed using propensity score-weighted logistic regression with stabilized inverse probability of treatment weights and doubly robust adjustment. Adjusted predicted probabilities and risk differences were estimated using marginal standardization.ResultsAmong 1,207 patients with non-cardioembolic stroke, vEND occurred in 22.2% using the primary definition (NIHSS increase ≥4 points) and in 25.8% using the secondary definition (NIHSS increase ≥2 points). vEND was more frequent in non-LAA than LAA stroke under both definitions (23.5% vs. 17.6% and 26.4% vs. 23.7%, respectively). Patients with LAA were more likely to receive DAPT than those without LAA (33.6% vs. 14.4%, p < 0.001). After weighting and adjustment, the association between antiplatelet therapy and vEND differed by stroke etiology (pinteraction<0.001 [primary] and pinteraction = 0.007 [secondary]). In LAA stroke, DAPT was associated with a numerically lower risk of vEND compared with SAPT (adjusted risk difference [primary definition]: −7.3%, 95% CI: −16.9% to 2.3%). In contrast, among non-LAA stroke patients, DAPT was associated with a higher vEND risk (adjusted risk difference [primary definition]: 16.6%, 95% CI: 7.1%–26.1%). Similar patterns were observed using the secondary vEND definition (NIHSS increase of ≥2 points).ConclusionVery early neurological deterioration within the first 24 h after non-cardioembolic stroke is common and occurs more frequently in non-LAA stroke. The association between DAPT and vEND appears to differ by stroke etiology. A lower risk was observed in LAA stroke, whereas the higher risk seen in non-LAA stroke likely reflects confounding by indication. Prospective studies are needed to determine whether intensified platelet inhibition may reduce vEND in LAA-related stroke. Introduction Early neurological deterioration (END) following stroke refers to a clinically significant worsening of neurological function shortly after the initial event. END is characterized by an increase in the National Institutes of Health Stroke Scale (NIHSS) score by 1–4 points during the acute phase, within the first 24 h up to hospital discharge [1, 2]. END is a clinical concern, as it is associated with poor clinical outcomes [3–5]. The reported incidence of END ranges from 6.7% to 19%, with few studies focusing on the first 24 h [2]. The causes of END are diverse and may include symptomatic intracranial hemorrhage, malignant cerebral edema, and progression of the ischemic lesion due to mechanisms like failure of recanalization or re-occlusion [1, 2, 6]. Dual antiplatelet therapy (DAPT), with aspirin and a P2Y12 inhibitor (e.g., clopidogrel), reduces recurrent stroke and improves outcomes in minor non-cardioembolic stroke or high-risk transient ischemic attack (TIA) compared to single antiplatelet therapy (SAPT, usually aspirin), but increases bleeding risk [7]. Current guidelines [8] recommend initiating DAPT within 24 h of symptom onset, highlighting the clinical relevance of assessing END. Evidence on the impact of DAPT on END remains scarce. A recent Austrian Stroke Registry analysis including patients with minor stroke (NIHSS <4) showed that DAPT was associated with a lower risk of END (OR 0.50; 95% CI: 0.35–0.72) and better 3-month functional outcomes compared with SAPT, in both large artery atherosclerotic (LAA) and non-LAA subtypes [9]. END was defined as an increase of >4 points in the NIHSS or recurrent stroke in another localization between admission and discharge. Additionally, the ARAMIS trial’s post hoc analysis indicated that DAPT might be superior to intravenous alteplase in preventing END in minor strokes without large vessel occlusion [10]. The ATAMIS trial compared DAPT with SAPT (aspirin) for the prevention of END (NIHSS increase >2 within 7 days) in patients with moderate ischemic stroke (NIHSS 4–10) [11]. DAPT reduced END compared to aspirin-based SAPT with a similar safety profile. A recent post hoc analysis explored whether this benefit differed by stroke etiology (LAA vs. non-LAA) [12]. It revealed a lower END rate in LAA patients receiving DAPT (adjusted risk difference: −10.4%, p = 0.001), but not in non-LAA patients. In a real-world 10-year cohort from a tertiary care center, we aimed to investigate the occurrence of very early neurological deterioration (vEND) within the first 24 h after admission in patients with non-cardioembolic ischemic stroke and examined its association with antiplatelet treatment strategy (DAPT vs. SAPT) and stroke etiology (LAA vs. non-LAA). Methods Study Design This single-center retrospective study included adults (≥18 years) with non-cardioembolic acute ischemic stroke admitted to the Cantonal Hospital St. Gallen between January 2014 and December 2023. Data were obtained from the Swiss Stroke Registry, including demographics, medical history, hospitalization details, complications, and follow-up outcomes. Antiplatelet regimens were supplemented from electronic health records. Patients declining research use of their data were excluded. The study was approved by the Ethics Committee of Eastern Switzerland following the STROBE guidelines [13]. Dual and Single Antiplatelet Therapy Patients were assigned to the DAPT group if: (1) antiplatelet therapy was indicated as acute therapy in the Swiss Stroke Registry; (2) a combination of aspirin and clopidogrel was started during hospitalization; and (3) DAPT was administered throughout hospitalization for index stroke. Patients treated acutely with only aspirin or clopidogrel (including pre-existing aspirin or clopidogrel monotherapy) were considered SAPT users. Stroke Etiology Stroke etiology was classified according to a modified TOAST (Trial of ORG 10172 in Acute Stroke Treatment) classification [14], distinguishing between large artery atherosclerosis, cardiac embolism (excluding patent foramen ovale or other rare cardiac causes), small vessel disease, cervical artery dissection, PFO (defined as the cause), other determined etiology, more than one possible etiology, and unknown etiology. Very Early Neurological Deterioration We defined very early neurological deterioration (vEND) as neurological worsening within 24 h after admission using 2 NIHSS thresholds: a definition of an increase of ≥4 points, and a definition of an increase of ≥2 points. Both the NIHSS score on admission and at 24 h are routinely assessed by neurologists. Statistical Analysis Descriptive analyses were performed stratified by antiplatelet regimen and stroke etiology (LAA vs. non-LAA). Continuous variables were compared using Wilcoxon rank-sum tests and categorical variables using chi-square tests. To estimate the association between DAPT and vEND, logistic regression models with robust variance estimators were used. To reduce confounding by treatment selection, propensity scores for initiation of DAPT were estimated for LAA and non-LAA patients using multivariable logistic regression including demographic, clinical, and vascular risk factors. Stabilized inverse probability of treatment weights (IPTWs) were calculated using the marginal treatment probability in the numerator and the propensity score in the denominator. Extreme weights were truncated at 10 (Table 2). Weighted logistic regression models including an interaction term between DAPT and stroke subtype were fitted to evaluate effect modification. To reduce confounding, the weighted outcome models were additionally adjusted for the same covariates used in the propensity score models (doubly robust estimation). Adjusted predicted probabilities and risk differences were estimated using marginal standardization. All models adjusted for age, baseline NIHSS, hypertension, diabetes, hyperlipidemia, coronary heart disease, peripheral artery disease, prior stroke, premorbid disability, low-density lipoprotein cholesterol levels, and systolic blood pressure. All analyses were performed with Stata (Version 17.0, StataCorp LLC, College Station TX). Continuous and ordinal variables are presented as medians with interquartile ranges, categorical variables as absolute numbers and percentages. We report 95% confidence intervals. p values <0.05 were considered statistically significant. Results Cohort Characteristics according to vEND, Antiplatelet Treatment Regimen, and Stroke Etiology In the final cohort of 1,207 patients with non-cardioembolic stroke, vEND occurred in 22.2% using the primary definition (NIHSS increase ≥4 points) and in 25.8% using the secondary definition (NIHSS increase ≥2 points) and was more frequent in non-LAA than LAA stroke under both definitions (23.5% vs. 17.6%, p = 0.04 and 26.4% vs. 23.7%, p = 0.38, respectively). Patients with vEND according to our primary definition had higher diastolic blood pressure on admission (median 88.0 mm Hg vs. 85.0 mm Hg, p = 0.047), were more likely to undergo perfusion imaging (39.9% vs. 29.0%, p = 0.002), and had longer door-to-imaging times (median 46.0 min vs. 33.0 min, p = 0.01) (online suppl. Table S1; for all online suppl. material, see https://doi.org/10.1159/000552952). Compared with SAPT-treated patients, those receiving DAPT were younger (median 68.9 years vs. 71.7 years, p = 0.03) and less frequently had arterial hypertension (67.9% vs. 75.0%, p = 0.03), prior ischemic stroke (8.0% vs. 17.7%, p < 0.001), coronary artery disease (2.7% vs. 11.9%, p < 0.001), and peripheral artery disease (0.9% vs. 4.2%, p = 0.02). Patients treated with DAPT were also less often pretreated with antihypertensive medication (42.4% vs. 52.5%, p = 0.01) or lipid-lowering therapy (8.0% vs. 26.1%, p < 0.001) but had higher total cholesterol (median 5.8 mmol/L vs. 5.4 mmol/L, p < 0.001) and low-density lipoprotein cholesterol levels on admission (3.7 mmol/L vs. 3.4 mmol/L, p < 0.001) (online suppl. Table S2). Similar differences between DAPT- and SAPT-treated patients were observed within both LAA and non-LAA subgroups (Table 1). Table 1.Baseline patient characteristics according to antiplatelet treatment regimen and stroke etiology​LAANon-LAATotal total (N = 262) DAPT (N = 88) SAPT (N = 174) p value total (N = 945) DAPT (N = 136) SAPT (N = 809) p value p value # Missings - N (%) Clinical characteristics Age, median (IQR), years72.4 (64.0–78.8)69.2 (61.5–76.9)73.8 (65.7–79.7)0.0170.8 (60.0–79.1)68.7 (59.1–77.9)71.2 (60.1–79.4)0.120.0580 (0) Female sex, n (%)82 (31.3)31 (35.2)51 (29.3)0.33401 (42.4)52 (38.2)349 (43.1)0.280.0010 (0) NIHSS on admission, median (IQR)2.0 (1.0–4.0)2.0 (1.0–3.0)2.0 (1.0–4.0)0.162.0 (1.0–4.0)2.0 (1.0–3.0)2.0 (1.0–4.0)0.570.260 (0) NIHSS at 24 h, median (IQR)1.0 (0.0–3.0)1.0 (0.0–3.0)1.0 (0.0–4.0)0.231.0 (0.0–3.0)2.0 (0.0–3.0)1.0 (0.0–3.0)0.090.95229 (19.0) Arterial hypertension, n (%)217 (82.8)64 (72.7)153 (87.9)0.002672 (71.1)88 (64.7)584 (72.2)0.08<0.0010 (0) Diabetes mellitus, n (%)72 (27.5)20 (22.7)52 (29.9)0.22208 (22.0)33 (24.3)175 (21.6)0.490.060 (0) Dyslipidemia, n (%)234 (89.3)81 (92.0)153 (87.9)0.31807 (85.4)116 (85.3)691 (85.4)0.970.100 (0) Actively smoking (or stopped < 2 years ago), n (%)89 (34.0)33 (37.5)56 (32.2)0.39230 (24.3)37 (27.2)193 (23.9)0.400.0020 (0) Prior ischemic stroke, n (%)57 (21.8)12 (13.6)45 (25.9)0.02135 (14.3)6 (4.4)129 (15.9)<0.0010.0030 (0) Prior TIA or amaurosis fugax, n (%)15 (5.7)5 (5.7)10 (5.7)0.9821 (2.2)2 (1.5)19 (2.3)0.520.0030 (0) Prior intracranial hemorrhage, n (%)3 (1.1)0 (0)3 (1.7)0.2215 (1.6)1 (0.7)14 (1.7)0.390.600 (0) Coronary artery disease, n (%)31 (11.8)3 (3.4)28 (16.1)0.00392 (9.7)3 (2.2)89 (11.0)0.0010.320 (0) Peripheral artery disease, n (%)12 (4.6)1 (1.1)11 (6.3)0.0631 (3.3)1 (0.7)30 (3.7)0.070.325 (0.4) Premorbid mRS, median (IQR)0.0 (0.0–1.0)0.0 (0.0-0.0)0.0 (0.0–1.0)0.110.0 (0.0–1.0)0.0 (0.0-0.0)0.0 (0.0–1.0)0.010.7997 (8.0) Body mass index, kg/m225.8 (23.5–28.1)25.0 (23.4–28.1)26.1 (23.6–28.1)0.4825.2 (23.2–28.1)26.2 (23.7–29.3)25.0 (23.1–27.9)0.0580.14323 (26.8) First systolic blood pressure in hospital (mm Hg) – median (IQR)165.0 (146.0–186.0)160.0 (141.5–184.0)169.0 (148.0–186.0)0.23163.0 (145.0–184.0)165.0 (145.5–185.0)163.0 (144.0–184.0)0.440.360 (0) First diastolic blood pressure in hospital, mm Hg– median (IQR)85.0 (78.0–92.0)85.0 (78.5–93.0)85.0 (78.0–92.0)0.6086.0 (78.0–95.0)89.0 (80.0–99.0)85.0 (78.0–95.0)0.010.120 (0)Prior medication Antihypertensive medication, n (%)154 (59.0)42 (47.7)112 (64.7)0.01456 (48.3)53 (39.0)403 (49.9)0.020.0022 (0.2) Lipid-lowering medication, n (%)75 (28.7)9 (10.2)66 (38.2)<0.001199 (21.1)9 (6.6)190 (23.5)<0.0010.013 (0.2)Admission laboratory​​​​​​​​​​ Glucose, mmol/L– median (IQR)6.5 (5.6–7.7)6.0 (5.4–7.7)6.7 (5.7–7.9)0.096.5 (5.7–7.7)6.3 (5.6–8.1)6.5 (5.7–7.6)0.850.96119 (9.9) Total cholesterol, mmol/L, median (IQR)5.4 (4.6–6.3)5.8 (5.1–6.7)5.3 (4.2–6.1)0.0045.6 (4.7–6.4)5.9 (5.0–6.5)5.5 (4.6–6.4)0.020.47136 (11.3) Low-density lipoprotein cholesterol, mmol/L, median (IQR)3.6 (2.8–4.2)3.7 (3.3–4.5)3.3 (2.4–4.1)<0.0013.5 (2.8–4.3)3.8 (3.2–4.3)3.5 (2.8–4.2)0.020.60144 (11.9)Admission imaging Cranial computed tomography angiography performed, n (%)257 (98.1)87 (98.9)170 (97.7)0.52921 (97.5)135 (99.3)786 (97.2)0.150.550 (0) Arterial vessel occlusion present on computed tomography angiography, n (%)97 (37.7)33 (37.9)64 (37.6)0.96136 (14.8)19 (14.1)117 (14.9)0.80<0.00131 (2.6) Anterior circulation46 (47.9)18 (54.5)28 (44.4)0.3561 (44.9)9 (47.4)52 (44.4)0.810.64​ Posterior circulation51 (54.8)15 (46.9)36 (59.0)0.2681 (61.4)11 (57.9)70 (61.9)0.740.33​ Perfusion imaging performed, n (%)69 (28.7)23 (28.7)46 (28.7)1.00282 (31.9)44 (36.4)238 (31.2)0.260.3583 (6.9) Door-to-imaging time (min), median (IQR)39.0 (18.0–99.0)44.5 (19.0–124.0)37.0 (17.0–92.0)0.2436.0 (19.0–92.0)31.0 (19.0–75.5)36.0 (19.0–94.0)0.390.81199 (16.5)DAPT, dual antiplatelet therapy; SAPT, single antiplatelet therapy; LAA, large artery atherosclerosis; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale.#For the comparison LAA vs. non-LAA (i.e., without considering the antiplatelet treatment regimen). For this comparison, patients with missing information on antiplatelet treatment regimen were not considered. Baseline patient characteristics according to antiplatelet treatment regimen and stroke etiology DAPT, dual antiplatelet therapy; SAPT, single antiplatelet therapy; LAA, large artery atherosclerosis; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale. #For the comparison LAA vs. non-LAA (i.e., without considering the antiplatelet treatment regimen). For this comparison, patients with missing information on antiplatelet treatment regimen were not considered. Table 2.Adjusted risk of vEND by antiplatelet therapy and stroke subtype Stroke subtype SAPT risk DAPT risk Risk difference 95% CI p value Primary vEND definition (NIHSS ≥4 point increase) LAA14.8%7.5%−7.3%−16.9%–2.3%0.14 Non-LAA15.1%31.7%16.6%7.1%–26.1%<0.001 Pinteraction<0.001​​​​​Secondary vEND definition (NIHSS ≥2 point increase) LAA20.5%13.1%−7.4%−18.6%–3.8%0.19 Non-LAA18.6%33.0%14.3%4.6%–24.1%0.004 Pinteraction = 0.007​​​​​DAPT, dual antiplatelet therapy; SAPT, single antiplatelet therapy; END, early neurological deterioration; LAA, large artery atherosclerosis; CI, confidence interval.Estimates are derived from inverse probability of treatment weighted (IPTW) logistic regression models adjusted for age, NIHSS at admission, hypertension, diabetes, hyperlipidemia, coronary heart disease, peripheral artery disease, prior stroke, premorbid disability, LDL quartiles, and systolic blood pressure. Adjusted risk of vEND by antiplatelet therapy and stroke subtype DAPT, dual antiplatelet therapy; SAPT, single antiplatelet therapy; END, early neurological deterioration; LAA, large artery atherosclerosis; CI, confidence interval. Estimates are derived from inverse probability of treatment weighted (IPTW) logistic regression models adjusted for age, NIHSS at admission, hypertension, diabetes, hyperlipidemia, coronary heart disease, peripheral artery disease, prior stroke, premorbid disability, LDL quartiles, and systolic blood pressure. Compared with LAA patients, non-LAA patients were more often female (42.4% vs. 31.3%, p = 0.001). Conversely, LAA patients more frequently had arterial hypertension (82.8% vs. 71.1%, p < 0.001), active smoking (34.0% vs. 24.3%, p = 0.002), and prior ischemic cerebrovascular events (ischemic stroke: 21.8% vs. 14.3%, p = 0.003; TIA: 5.7% vs. 2.2%, p = 0.003). In addition, they were more frequently pretreated with antihypertensive (59.0% vs. 48.3%, p = 0.002) and lipid-lowering medication (28.7% vs. 21.1%, p = 0.01), and more often received DAPT during hospitalization (33.6% vs. 14.4%, p < 0.001). Within the non-LAA group, 403 (42.8%) patients were classified as having an unknown stroke etiology, including both cases with complete diagnostic evaluation and those with incomplete evaluation. Outcome and Interaction Analyses In IPTW-weighted regression analyses, the association between DAPT and vEND differed according to stroke etiology (pinteraction<0.001 [primary] and pinteraction = 0.007 [secondary], respectively). Among patients with LAA stroke, the risk of vEND was numerically lower in DAPT-treated, although this did not reach statistical significance (adjusted risk difference: [primary definition] −7.3%, 95% CI −16.9% to 2.3% [secondary definition] −7.4%, 95% CI: −18.6% to 3.8%). In contrast, among patients without LAA, DAPT was associated with a higher risk of vEND (adjusted risk difference: [primary definition] 16.6%, 95% CI: 7.1%–26.1% [secondary definition] 14.3%, 95% CI: 4.6%–24.1%). Standardized mean differences after IPTW are presented in online supplemental Table S3, and adjusted odds ratios are shown in online supplemental Table S4. Discussion In this cohort of patients with acute non-cardioembolic ischemic stroke, the association between DAPT and vEND differed according to stroke etiology. While DAPT was associated with a numerically lower vEND risk among patients with LAA, the opposite association was observed in patients without LAA. The significant interaction between antiplatelet treatment and stroke subtype suggests heterogeneity in the relationship between platelet inhibition intensity and very early neurological worsening. Early neurological deterioration is thought to result from multiple mechanisms, including infarct progression, hemodynamic instability, and systemic complications [1, 3, 15, 16]. In LAA, however, platelet activation and artery-to-artery embolization from unstable atherosclerotic plaques play a central role [17, 18]. Intensified platelet inhibition may therefore reduce thrombus propagation or recurrent microembolization and thereby lower the risk of neurological deterioration [7]. Evidence from randomized trials supports the benefit of early DAPT [19, 20]. In the INSPIRES trial, DAPT with aspirin and clopidogrel reduced the risk of recurrent stroke compared with aspirin alone [21]. Similarly, in the ATAMIS trial, DAPT significantly reduced early neurological deterioration compared with aspirin alone [11]. A post hoc analysis suggested that this benefit may be particularly pronounced among patients with LAA stroke, whereas no clear effect was observed in non-LAA [12]. In our cohort, the association between DAPT and vEND differed in patients without LAA, where DAPT was associated with a higher risk of vEND. A likely explanation is confounding by indication. In routine clinical practice, clinicians may preferentially initiate DAPT in patients perceived to be at higher risk of early deterioration. At the same time, baseline characteristics differed between treatment groups: patients receiving DAPT were generally younger and had fewer cardiovascular comorbidities. In the LAA subgroup, DAPT-treated patients were younger and had lower rates of cardiovascular comorbidities, supporting the presence of treatment selection toward patients with fewer comorbidities. These findings suggest that differences in prior medication may reflect both variability in outpatient management and treatment selection in the acute setting. Although our analyses incorporated propensity score weighting and doubly robust adjustment, residual confounding cannot be excluded. The early post-stroke period represents a particularly vulnerable phase. In ATAMIS, early neurological deterioration occurred more frequently among patients with LAA compared with those without LAA [11]. In contrast, in our cohort vEND within the first 24 h occurred more frequently in patients without LAA. This discrepancy may reflect differences in study populations and stroke severity. Moreover, our analysis specifically focused on very early worsening within the first 24 h, a time window that has been less frequently investigated but may represent a critical phase of stroke evolution. Our findings have potential clinical implications. While current guidelines [8, 22] support early DAPT initiation in selected patients with minor non-cardioembolic stroke or high-risk TIA, our results suggest that stroke etiology may modify the association between antiplatelet therapy and vEND. Patients with LAA may derive greater benefit from intensified platelet inhibition during the hyperacute phase after stroke. Conclusions In this real-world cohort of patients with non-cardioembolic stroke, DAPT showed heterogeneous associations with vEND depending on stroke etiology. While a lower risk was observed in LAA stroke, no protective association was seen in non-LAA stroke. These findings highlight the potential importance of stroke-mechanism-specific antiplatelet strategies, which should be evaluated in prospective studies. Limitations Several limitations should be considered. This was a retrospective single-center study without randomized treatment allocation. Although propensity score weighting and doubly robust adjustment were applied to reduce confounding, residual confounding by indication cannot be excluded. Information on antiplatelet loading doses and treatment duration was not available. Antiplatelet exposure was defined as newly initiated DAPT during hospitalization that was continued until discharge. Because vEND occurred within the first 24 h, treatment classification may reflect clinical decisions made after early neurological worsening. However, antiplatelet strategy is typically determined early during hospitalization, so discharge medication likely reflects the intended treatment strategy. Despite the exclusion of patients with confirmed cardioembolic stroke, the non-LAA group likely includes patients with embolic stroke patterns without an identified cardiac source, which may have influenced the associations Figure 1. Flowchart. AIS, acute ischemic stroke; TIA, transient ischemic attack; TOAST, Trial of ORG 10172 in acute stroke treatment; NIHSS, National Institutes of Health Stroke Scale; MRI, magnetic resonance imaging. Statement of Ethics This study was approved by the Ethics Committee of Eastern Switzerland (EKOS ID: 2024-00119) in advance. Written consent was not acquired; as, in accordance with Swiss legislation, enrollment in the Swiss Stroke Registry (SSR) is mandated for quality assurance measures. Patients are notified about the potential utilization for research with the provision that individuals who dissent on the use of their data are excluded from research projects. Patients were informed about the use of their routinely collected data for research purposes. Patients who refused the use of their data were excluded from the analysis. Conflict of Interest Statement T.R.S. was supported by the Bangerter-Rhyner Foundation. The remaining authors report no conflicts of interest relevant to this study. Funding Sources The study received support through a grant from the Research Committee of HOCH Health Ostschweiz for Tolga Dittrich's Early-Career Research Group. Author Contributions T.D.D. and G.M.D.M. planned the work. T.D.D., R.P., S.S., S.B., F.V., and D.V. acquired the data and drafted the manuscript. T.D.D. performed the analyses. T.D.D., G.M.D.M., R.P., S.S., S.B., F.V., D.V., T.S., and V.H. interpreted the results and substantially contributed to the final manuscript;Guarantor: T.D.D.